Live Breaking News & Updates on Diabetic gastroparesis market research

Stay informed with the latest breaking news from Diabetic gastroparesis market research on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Diabetic gastroparesis market research and stay connected to the pulse of your community

Diabetic Foot Ulcer Treatment Market Expected to Witness a High Jump as the Market is Projected to Grow with a CAGR of 17.0% During the Study Period (2018-2030)


leading cause of non-traumatic lower extremity amputations in the United States, and approximately
14-24% of patients with diabetes who develop a foot ulcer will require an
amputation. Foot ulceration precedes
85% of diabetes-related amputations.
The gold standard for Diabetic Foot Ulcer treatment includes debridement of the wound, management of any infection, revascularization procedures when indicated, and off-loading of the ulcer.
Currently, the market is mainly dominated by
off-label generic drugs such as analgesics and anti-infectives,
around 78% of the current market is captured by these two classes of drugs. 
There is only one drug,
Regranex (Becaplermin), which the FDA has approved.
Regranex gel uses a Platelet-derived growth factor (PDGF) for the Diabetic Neuropathic Ulcer treatment formulated to act as a first-line treatment following effective ulcer care. The US FDA had approved the biologics license application of Becaplermin (OMJ Pharmaceuticals, Inc) in December 1997.

Germany , Italy , Japan , United-states , United-kingdom , France , Spain , Shruti-thakur , Amniox-tissuetech , Donaperminogene-seltoplasmid , Regranex-becaplermin , Ticeba-gmb